CYTOKINES AS POTENTIAL MARKERS OF COVID-19 SEVERITY AND OUTCOMES

Keywords: COVID-19, Coronavirus, Cytokines, Cytokine release syndrome

Abstract

The continual propagation of SARS-CoV-2 has changed health care systems globally. Ranging degrees of clinical severity in COVID-19 patients have been noted in numerous literature sources. Cytokines play a crucial role in the development of key immunological processes in COVID-19. SARS-CoV-2 causes imbalance of the immune system and might culminate in cytokine storm and multiple organ involvement. The prevailing role of some special cytokines might serve as indicators of disease severity. Further stratification of patients in the context of specific cytokines can be beneficial for diagnosing disease stages. It can prevent critical states owing to timely diagnosis and targeted therapy. Targeting peculiar cytokines can markedly reduce complications. The aim of this article is to comprehensively overview the role of the main cytokines in COVID-19 pathogenesis and distinguish prognostic factors. Insights into specific cytokine involvement in COVID-19 pathogenesis may open new avenues for diagnosing hyperinflammatory COVID-19, predicting its outcomes and providing individualized cytokine-targeted therapeutic approaches.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

WHO Novel Coronavirus-China. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf (Accessed 7 Feb 2022).

Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) Available from: http://en.nhc.gov.cn/2020-03/29/c_78469.htm (Accessed 7 Feb 2022).

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733.

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 2020;39(6):1011–1019.

Loisa P, Rinne T, Laine S, Kaukinen S. Anti‐inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 2003;47(3):319–325.

Jose RJ, Manuel A. COVID‐19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):e46–e47.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011;31(11):1409–1417.

Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses 2010;2(8):1804–1820.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their

roles in pathogenesis. J Microbiol Immunol Infect 2021;54(2):159–163.

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368(6490):473–474.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280e8.

Moradian N, Gouravani M, Salehi MA, Heidari A, Shafeghat M, Hamblin MR, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw 2020;31(3):81–93.

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest 2020;158(4):1397–1408.

Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020;27(6):992–1000.e3.

Bobcakova A, Petriskova J, Vysehradsky R, Kocan I, Kapustova L, Barnova M, et al. Immune profile in patients with COVID-19: Lymphocytes exhaustion markers in relationship to clinical outcome. Front Cell Infect Microbiol 2021;11:646688.

Lavillegrand JR, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care 2021;11(1):9.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497– 506.

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS‐CoV‐2 infected patients. EBioMedicine 2020;55:102763.

Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol 2020;30(6):1-9.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19:102537.

Buonaguro FM, Puzanov I, Ascierto PA. Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med 2020;18:165.

Wan S, Yi Q, Fan S, Jinglong L, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 189(3):428-37.

Kesmez Can F, Özkurt Z, Öztürk N, Sezen S. Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. Int J Clin Pract 2021;75(12):e14970.

Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A, Naranjo L, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. J Allergy Clin Immunol 2020;146(4):799-807.e9.

Taha SI, Samaan SF, Ibrahim RA, El-Sehsah EM, Youssef MK. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw 2021;32(4):83–88.

Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci. 2021;18(6):1356–1362.

Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. HNF Hospital Tocilizumab multidisciplinary team. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis 2020;99:491–495.

San-Juan R, Fernández-Ruiz M, López-Medrano F, Carretero O, Lalueza A, de la Calle GM, et al. H12O Immunomodulation Therapy for COVID-19 Group, the Spanish Network for Research in Infectious Diseases (REIPI). Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. Int J Infect Dis 2022;117:56–64.

Sánchez-Rovira P, Pérez-Chica G, Ortega-Granados AL, Aguilar-García J, Díaz-Beltrán L, Gálvez-Montosa F, et al. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission. Medicine (Baltimore) 2021;100(29):e26533.

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: Survival and clinical outcomes. Chest 2020;158(4):1397–1408.

Bonnet B, Cosme J, Dupuis C, Coupez E, Adda M, Calvet L, et al. Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation. EBioMedicine 2021;73:103622.

Qin S, Jiang Y, Wei X, Liu X, Guan J, Chen Y, et al. Dynamic changes in monocytes subsets in COVID-19 patients. Hum Immunol 2021;82(3):170–176.

Mert A, Vahaboğlu H, Arslan F, Batirel A, Saraçoğlu KT, Bastug A, et al. Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. Rheumatol Int 2022;42(3):457–467.

Mardi A, Meidaninikjeh S, Nikfarjam S, Majidi Zolbanin N, Jafari R. Interleukin-1 in COVID-19 infection: Immunopathogenesis and possible therapeutic perspective. Viral Immunol 2021;34(10):679–688.

Vanderbeke L, Van Mol P, Van Herck Y, De Smet F, Humblet-Baron S, Martinod K, et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun 2021;12(1):4117.

Kahn R, Schmidt T, Golestani K, Mossberg A, Gullstrand B, Bengtsson AA, et al. Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19. J Leukoc Biol 2021;109(1):115–120.

Bergantini L, d'Alessandro M, Cameli P, Otranto A, Luzzi S, Bianchi F, et al. Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis. Cytokine 2022;151:155804.

Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, et al. Interleukin-1 andinterleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study. Lancet Rheumatol 2021;3:e253–e261.

Ragusa R, Basta G, Del Turco S, Caselli C. A possible role for ST2 as prognostic biomarker for COVID-19. Vascul Pharmacol 2021;138:106857.

Zeng Z, Hong XY, Li Y, Chen W, Ye G, Li Y, et al. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med 2020;14(17):1619-1629.

Hu H, Pan H, Li R, He K, Zhang H, Liu L. Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: A systematic review and meta-analysis. Front Pharmacol 2022;13:802228.

Li L, Li J, Gao M, Fan H, Wang Y, Xu X, et al. Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients. Front Immunol 2021;11:602395.

Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. Eur J Med Res 2015;20(1):7.

Li W, Sun W, Liu L, Yang F, Li Y, Chen Y, et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol 2010;185(9):5056–5065.

Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020;9(1):1123–1130.

Li J, Rong L, Cui R, Feng J, Jin Y, Chen X, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. Ann Palliat Med 2021;10(4):3706–3714.

Abushouk A, Nasr A, Masuadi E, Allam G, Siddig EE, Fahal AH. The Role of Interleukin-1 cytokine family (IL-1β, IL-37) and interleukin-12 cytokine family (IL-12, IL-35) in eumycetoma infection pathogenesis. PLoS Negl Trop Dis 2019;13(4):e0007098.

Jia H, Liu J, Han B. Reviews of interleukin-37: Functions, receptors, and roles in diseases. Biomed Res Int 2018;2018:3058640.

Li A, Ling Y, Song Z, Cheng X, Ding L, Jiang R, et al. Correlation between early plasma interleukin 37 responses with low inflammatory cytokine levels and benign clinical outcomes in severe acute respiratory syndrome coronavirus 2 Infection. J Infect Dis 2021;223(4):568–580.

Chau AS, Weber AG, Maria NI, Narain S, Liu A, Hajizadeh N, et al. The longitudinal immune response to coronavirus disease 2019: Chasing the cytokine storm. Arthritis Rheumatol 2021;73(1):23–35.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762–768.

Wen XS, Jiang D, Gao L, Zhou JZ, Xiao J, Cheng XC, et al. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis 2021;21(1):57.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang T, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620-2629.

Alosaimi B, Mubarak A, Hamed ME, Almutairi AZ, Alrashed AA, AlJuryyan A, et al. Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and In-hospital mortality. Front Immunol 2021;12:668725.

Henry BM, Szergyuk I, de Oliveira MHS, Lippi G, Benoit JL, Vikse J, et al. Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state. J Med Virol 2021;93(9):5515–5522.

Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and coagulopathy in COVID-19. Curr Probl Cardiol 2021;46(3):100742.

Ali MAM, Spinler SA. COVID-19 and thrombosis: From bench to bedside. Trends Cardiovasc Med 2021;31(3):143–160.

Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020;12(570):eabd3876.

Luo HC, You CY, Lu SW, Fu YQ. Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol 2021;100(1):45–52.

Liu Y, Gao W, Guo W, Guo Y, Shi M, Dong G, et al. Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19. J Thromb Thrombolysis 2020;50(4):825–832.

Robba C, Battaglini D, Ball L, Valbusa A, Porto I, Della Bona R, et al. Coagulative disorders in critically Ill COVID-19 patients with acute distress respiratory syndrome: A critical review. J Clin Med 2021;10(1):140.

Wang J, Yang X, Li Y, Huang JA, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. Virol J 2021;18(1):117.

Petrey AC, Qeadan F, Middleton EA, Pinchuk IV, Campbell RA, Beswick EJ. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J Leukoc Biol 2021;109(1):55–66.

Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A, et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol 2021;12:700782.

Nossent EJ, Schuurman AR, Reijnders TDY, Saris A, Jongerius I, Blok SG, et al. Pulmonary procoagulant and innate immune responses in critically ill COVID-19 patients. Front Immunol 2021;12:664209.

Sánchez D, Hernández-Gilsoul T, Tapia-Rodríguez M, Gómez-Martín D. Neutrophil extracellular traps contribute to COVID-19 hyperinflammation and humoral autoimmunity. Cells 2021;10(10):2545.

Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci 2020;13:1077–1086.

Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W, et al. Antiphospholipid antibodies in critically ill patients with COVID19. Arthritis Rheumatol 2020;72(12):1998–2004.

Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021;40(7):2611–2619.

Report of the WHO-China Joint Mission on Coronavirus Disease 19 (COVID-19). Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19) (Accessed 7 Feb 2022).

Núñez-Torrón C, Ferrer-Gómez A, Moreno Moreno E, Pérez-Mies B, Villarrubia J, Chamorro S, et al. Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. J Clin Pathol 2021:jclinpath-2020-207337.

Goel N, Goyal N, Kumar R. Long COVID mimicking interstitial lung disease: A case series. Curr Health Sci J 2021;47(3):469–473.

Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020;39(7):2055–2062.

Sukrisman L, Sinto R, Priantono D. Hematologic profiles and correlation between absolute lymphocyte count and neutrophil/lymphocyte ratio with markers of inflammation of COVID-19 in an Indonesian National Referral Hospital. Int J Gen Med 2021;14:6919–6924.

Bülow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine 2021;138:155389.

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; What we know so far. Front Immunol 2020;11:1446.

Published
2022-03-29